Envestnet Asset Management Inc. Sells 15,252 Shares of United Therapeutics Corporation $UTHR

Envestnet Asset Management Inc. cut its position in United Therapeutics Corporation (NASDAQ:UTHR) by 20.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,820 shares of the biotechnology company’s stock after selling 15,252 shares during the period. Envestnet Asset Management Inc. owned about 0.13% of United Therapeutics worth $24,239,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently modified their holdings of UTHR. AQR Capital Management LLC increased its stake in United Therapeutics by 40.1% in the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after buying an additional 364,713 shares in the last quarter. Invesco Ltd. boosted its stake in shares of United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares during the period. Assetmark Inc. grew its position in shares of United Therapeutics by 38.1% during the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after purchasing an additional 197,384 shares in the last quarter. Norges Bank bought a new stake in United Therapeutics during the 2nd quarter valued at approximately $136,453,000. Finally, Amundi lifted its holdings in United Therapeutics by 3.6% in the 2nd quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock worth $107,113,000 after purchasing an additional 12,633 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on UTHR. Jefferies Financial Group reaffirmed a “buy” rating and set a $575.00 price objective on shares of United Therapeutics in a report on Wednesday, November 19th. Wells Fargo & Company upped their target price on shares of United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. HC Wainwright raised their target price on shares of United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. UBS Group boosted their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Stock Down 0.5%

UTHR stock opened at $473.66 on Friday. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $519.99. The stock has a market capitalization of $20.40 billion, a price-to-earnings ratio of 17.95, a price-to-earnings-growth ratio of 2.53 and a beta of 0.85. The firm’s fifty day simple moving average is $486.02 and its two-hundred day simple moving average is $432.54.

Insider Activity

In other news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, November 17th. The stock was sold at an average price of $470.43, for a total value of $10,584,675.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders sold a total of 502,214 shares of company stock worth $242,241,993 in the last ninety days. 10.30% of the stock is owned by insiders.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.